# Certara Reports Fourth Quarter 2025 Financial Results; Provides Full Year 2026 Guidance
Canonical URL: https://biopharmsignal.com/news/CERT/certara-reports-fourth-quarter-2025-financial-results-provides-full-year-2026-guidance
Ticker: CERT
Company: Certara
Source: Certara
Published: 2026-02-26 11:00 EST
Original Source URL: https://ir.certara.com
## Summary

FY 2025 Revenue of $418.8M (9% growth) and Adj. EBITDA of $134.5M (10% growth) Fourth Quarter Revenue of $103.6M (3% growth) and Adj. EBITDA of $32.5M (-3% decline) FY 2026 Revenue Growth of 0-4% FY 2026 Adjusted EBITDA Margin of 30-32% FY 2026 Adjusted Diluted EPS of $0.44-$0.48 RADNOR, Pa., Feb.

## Article Body
FY 2025 Revenue of $418.8M (9% growth) and Adj. EBITDA of $134.5M (10% growth) Fourth Quarter Revenue of $103.6M (3% growth) and Adj. EBITDA of $32.5M (-3% decline) FY 2026 Revenue Growth of 0-4% FY 2026 Adjusted EBITDA Margin of 30-32% FY 2026 Adjusted Diluted EPS of $0.44-$0.48 RADNOR, Pa., Feb.
## Recent Company News
- 2026-05-11 10:25 EST — [Certara Reports First Quarter 2026 Financial Results](https://biopharmsignal.com/news/CERT/certara-reports-first-quarter-2026-financial-results) — Source: Certara
- 2026-04-22 11:00 EST — [Certara Enters Definitive Agreement for the Sale of its Regulatory and Medical Writing Business to Veristat](https://biopharmsignal.com/news/CERT/certara-enters-definitive-agreement-for-the-sale-of-its-regulatory-and-medical-writing-business-to-veristat) — Source: Certara
- 2026-04-09 20:15 EST — [Certara to Report First Quarter 2026 Financial Results on May 11th, 2026](https://biopharmsignal.com/news/CERT/certara-to-report-first-quarter-2026-financial-results-on-may-11th-2026) — Source: Certara
- 2026-03-03 13:00 EST — [Certara Simcyp® Simulator Results Replace Ten Human Trials for Chronic Myeloid Leukemia (CML) Therapy asciminib](https://biopharmsignal.com/news/CERT/certara-simcypr-simulator-results-replace-ten-human-trials-for-chronic-myeloid-leukemia-cml-therapy-asciminib) — Source: Certara
- 2026-02-27 13:30 EST — [Certara to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/CERT/certara-to-participate-in-upcoming-investor-conferences) — Source: Certara
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)